Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Labetalol has:
A. More potent β adrenergic blocking than α
blocking activity
B. More potent α adrenergic blocking than β
blocking activity
C. Equal α and β adrenergic blocking activity
D. β1 agonistic activity in addition to α and β
adrenergic blockade
by

1 Answer

Answer :

A. More potent β adrenergic blocking than α
blocking activity
by

Related questions

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Last Answer : C. Do not block any effect of injected adrenaline

Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve stimulation

Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve stimulation

Last Answer : C. Do not block any effect of injected adrenaline

Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are corre

Description : Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are corre

Last Answer : D. Both ‘B’ and ‘C’ are correct

Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are correct

Description : Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are correct

Last Answer : D. Both ‘B’ and ‘C’ are correct

The following drug claimed to have a therapeutic effect in senile dementia has α adrenergic blocking activity: A. Piracetam B. Pyritinol C. Codergocrine D. Methylphenidate

Description : The following drug claimed to have a therapeutic effect in senile dementia has α adrenergic blocking activity: A. Piracetam B. Pyritinol C. Codergocrine D. Methylphenidate

Last Answer : C. Codergocrine

Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Description : Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Last Answer : C. Transducer pathway of response effectuation

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Ergotamine relieves migraine by: A. Blocking vascular α adrenergic receptors B. Blocking vascular 5-HT2 receptors C. Dilating cranial arterio-venous shunt channels D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Description : Ergotamine relieves migraine by: A. Blocking vascular α adrenergic receptors B. Blocking vascular 5-HT2 receptors C. Dilating cranial arterio-venous shunt channels D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Last Answer : D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Description : The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Last Answer : A. It is a weak Na+ channel blocker

Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

Anthelmintic action of piperazine is due to: A. Interference with ATP generation in the worm B. Blockade of glucose uptake by the worm C. Hyperpolarization of nematode muscle by GABA agonistic action D. Depolarization of nematode muscle by activating nicotinic receptors

Description : Anthelmintic action of piperazine is due to: A. Interference with ATP generation in the worm B. Blockade of glucose uptake by the worm C. Hyperpolarization of nematode muscle by GABA agonistic action D. Depolarization of nematode muscle by activating nicotinic receptors

Last Answer : C. Hyperpolarization of nematode muscle by GABA agonistic action

Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Description : Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Last Answer : C. Intrinsic sympathomimetic activity

Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Description : Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Last Answer : C. Intrinsic sympathomimetic activity

The quarternary analogues of belladonna alkaloids are preferred over the natural alkaloids for antisecretory/ antispasmodic indications because: A. They have additional nicotinic receptor blocking activity B. They are incompletely absorbed after oral administration C. They are devoid of CNS and ocular effects D. Dose to dose they are more potent than atropine

Description : The quarternary analogues of belladonna alkaloids are preferred over the natural alkaloids for antisecretory/ antispasmodic indications because: A. They have additional nicotinic receptor blocking activity B. They are ... of CNS and ocular effects D. Dose to dose they are more potent than atropine

Last Answer : C. They are devoid of CNS and ocular effects

Which of the following is a long acting neuroleptic having specific antidopaminergic action, but little adrenergic or cholinergic blocking activity: A. Triflupromazine B. Thioridazine C. Clozapine D. Pimozide

Description : Which of the following is a long acting neuroleptic having specific antidopaminergic action, but little adrenergic or cholinergic blocking activity: A. Triflupromazine B. Thioridazine C. Clozapine D. Pimozide

Last Answer : D. Pimozide

Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Description : Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Last Answer : C. Agonistic action on vascular α2 adrenergic receptors

Adrenergic β1 selective blockers offer the following advantages except: A. Lower propensity to cause bronchospasm B. Less prone to produce cold hands and feet as side effect C. Withdrawal is less likely to exacerbate angina pectoris D. Less liable to impair exercise capacity

Description : Adrenergic β1 selective blockers offer the following advantages except: A. Lower propensity to cause bronchospasm B. Less prone to produce cold hands and feet as side effect C. Withdrawal is less likely to exacerbate angina pectoris D. Less liable to impair exercise capacity

Last Answer : C. Withdrawal is less likely to exacerbate angina pectoris

Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

Tyrosine kinase activity is present in (A) α-Adrenergic receptors (B) β-Adrenergic receptors (C) Cholinergic receptors (D) Insulin receptors

Description : Tyrosine kinase activity is present in (A) α-Adrenergic receptors (B) β-Adrenergic receptors (C) Cholinergic receptors (D) Insulin receptors

Last Answer : Answer : D

The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

Dihydroergotamine (DHE) differs from ergotamine in the following respect: A. It is a more potent oxytocic B. It has antiemetic property C. It has high oral bioavailability D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Description : Dihydroergotamine (DHE) differs from ergotamine in the following respect: A. It is a more potent oxytocic B. It has antiemetic property C. It has high oral bioavailability D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Last Answer : D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Olanzapine has the following features except: A. It is an antipsychotic drug with weak D2 receptor blocking action B. It has potent 5-HT2 blocking and antimuscarinic actions C. It lowers seizure threshold D. It produces prominent extrapyramidal side effects

Description : Olanzapine has the following features except: A. It is an antipsychotic drug with weak D2 receptor blocking action B. It has potent 5-HT2 blocking and antimuscarinic actions C. It lowers seizure threshold D. It produces prominent extrapyramidal side effects

Last Answer : D. It produces prominent extrapyramidal side effect

Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Description : Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Last Answer : D. All of the above

Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

Sulbactam differs from clavulanic acid in that: A. It is not a progressive inhibitor of β-lactamase B. It does not inhibit β-lactamase produced by gram negative bacilli C. It is quantitatively more potent D. It per se inhibits N.gonorrhoeae

Description : Sulbactam differs from clavulanic acid in that: A. It is not a progressive inhibitor of β-lactamase B. It does not inhibit β-lactamase produced by gram negative bacilli C. It is quantitatively more potent D. It per se inhibits N.gonorrhoeae

Last Answer : D. It per se inhibits N.gonorrhoeae

Choose the correct statement about long acting calcium channel blocking drugs as antihypertensives: A. They are the most effective drugs in suppressing hypertensive left ventricular hypertrophy B. They are as effective as diuretics or β blockers in reducing cardiovascular/total mortality C. They compromise quality of life more than β blockers D. They have no beneficial effect in hypertensive/diabetic nephropath

Description : Choose the correct statement about long acting calcium channel blocking drugs as antihypertensives: A. They are the most effective drugs in suppressing hypertensive left ventricular hypertrophy B. They ... more than β blockers D. They have no beneficial effect in hypertensive/diabetic nephropath

Last Answer : B. They are as effective as diuretics or β blockers in reducing cardiovascular/total mortality

Low dose therapy with the following category of antihypertensive drugs has been found to be more advantageous in the long-term than high dose therapy with the same drugs: A. β adrenergic blockers B. α1 adrenergic blockers C. Central sympatholytics D. Diuretics

Description : Low dose therapy with the following category of antihypertensive drugs has been found to be more advantageous in the long-term than high dose therapy with the same drugs: A. β adrenergic blockers B. α1 adrenergic blockers C. Central sympatholytics D. Diuretics

Last Answer : D. Diuretics

The quarternary analogues of belladonna alkaloids are preferred over the natural alkaloids for antisecretory/ antispasmodic indications because: A. They have additional nicotinic receptor blocking activity B. They are incompletely absorbed after oral administration C. They are devoid of CNS and ocular effects D. Dose to dose they are more potent than atropine

Description : The quarternary analogues of belladonna alkaloids are preferred over the natural alkaloids for antisecretory/ antispasmodic indications because: A. They have additional nicotinic receptor blocking activity B. They are ... of CNS and ocular effects D. Dose to dose they are more potent than atropine

Last Answer : C. They are devoid of CNS and ocular effects

Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl noradrenaline which acts as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Description : Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl ... as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Last Answer : B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone

6.12 The most prominent action of bromocriptine is: A. Dopamine D2 agonism B. Dopamine D2 antagonism C. Dopamine D1 antagonism D. α adrenergic antagonism

Description : 6.12 The most prominent action of bromocriptine is: A. Dopamine D2 agonism B. Dopamine D2 antagonism C. Dopamine D1 antagonism D. α adrenergic antagonism

Last Answer : A. Dopamine D2 agonism

Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Description : Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Last Answer : C. It does not concurrently enhance noradrenaline release

Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Description : Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Last Answer : A. Adrenaline

Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Description : Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Last Answer : C. It does not concurrently enhance noradrenaline release

The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Description : The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Last Answer : B. Ergotamine

The nonselective α adrenergic blockers produce the following actions except: A. Postural hypotension B. Bradycardia C. Miosis D. Inhibition of ejaculation

Description : The nonselective α adrenergic blockers produce the following actions except: A. Postural hypotension B. Bradycardia C. Miosis D. Inhibition of ejaculation

Last Answer : B. Bradycardia

Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Description : Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Last Answer : A. Adrenaline

The α 2 adrenoceptors are: A. Located exclusively on the adrenergic nerve endings B. Prejunctional, postjunctional as well as extrajunctional in location C. Selectively activated by phenylephrine D. Selectively blocked by clonidine

Description : The α 2 adrenoceptors are: A. Located exclusively on the adrenergic nerve endings B. Prejunctional, postjunctional as well as extrajunctional in location C. Selectively activated by phenylephrine D. Selectively blocked by clonidine

Last Answer : B. Prejunctional, postjunctional as well as extrajunctional in location

The following is an α 2 adrenergic agonist used as eyedrops to lower intraocular pressure: A. Brinzolamide B. Bambuterol C. Brimonidine D. Latanoprost

Description : The following is an α 2 adrenergic agonist used as eyedrops to lower intraocular pressure: A. Brinzolamide B. Bambuterol C. Brimonidine D. Latanoprost

Last Answer : C. Brimonidine

The following is true of β-adrenergic blocker therapy in CHF: A. They are added to conventional therapy after cardiac compensation is restored B. They are indicated only in severe (NYHA class IV) heart failure C. They are to be used only at low doses D. All of the above

Description : The following is true of β-adrenergic blocker therapy in CHF: A. They are added to conventional therapy after cardiac compensation is restored B. They are indicated only in severe (NYHA class IV) heart failure C. They are to be used only at low doses D. All of the above

Last Answer : A. They are added to conventional therapy after cardiac compensation is restored

Insulin release from pancreatic β cells is augmented by the following except: A. Ketone bodies B. Glucagon C. Vagal stimulation D. Alfa adrenergic agonists

Description : Insulin release from pancreatic β cells is augmented by the following except: A. Ketone bodies B. Glucagon C. Vagal stimulation D. Alfa adrenergic agonists

Last Answer : D. Alfa adrenergic agonist

The basis for use of β-adrenergic blockers in congestive heart failure (CHF) is: A. They exert positive inotropic effect in CHF B. They counteract deleterious effect of sympathetic overactivity on the myocardium C. They exert antiischaemic effect on the heart D. They prevent cardiac arrhythmias

Description : The basis for use of β-adrenergic blockers in congestive heart failure (CHF) is: A. They exert positive inotropic effect in CHF B. They counteract deleterious effect of sympathetic overactivity on the myocardium C. They exert antiischaemic effect on the heart D. They prevent cardiac arrhythmias

Last Answer : B. They counteract deleterious effect of sympathetic overactivity on the myocardium